Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG4101 in Hepatocellular Carcinoma After TACE
NCT02854839Phase 2Completed
- Sponsor
- GC Cell
- Start
- Nov 2016
- Primary completion
- Sep 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MG4101 in hepatocellular carcinoma (HCC), sponsored by GC Cell. Started Nov 2016; status: completed.
02
Drugs
MG4101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02854839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854839.